SOURCE: StockCall

StockCall

May 30, 2012 08:20 ET

Equity Research on Perrigo Co. and Auxilium Pharmaceuticals Inc. - Generic Launches and Lawsuits Dominate Drug Related Product News

JOHANNESBURG, SOUTH AFRICA--(Marketwire - May 30, 2012) - www.stockcall.com/ offers investors comprehensive research on the Drug Related Products industry and has completed analytical research on Perrigo Co. (NASDAQ: PRGO) and Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL). Register with us today at www.stockcall.com/ to have free access to these researches.

The drug related products industry has been awash in generic drug news as of late. Some companies have been successful in launching generic versions of top brand-name drugs, while others have been suing to prevent such actions. Register now at https://stockcall.com/development/stockcall/page.php?name=register.html to have free access to our reports on the Drug Related Products industry.

www.stockcall.com/ is an online platform where investors doing their due-diligence on the Drug Related Products industry can have easy and free access to our analyst research and opinions on Perrigo Co. and Auxilium Pharmaceuticals Inc.; investors and shareholders of these companies can simply register for a complimentary membership at https://stockcall.com/development/stockcall/page.php?name=register.html.

On the court side of things, Auxilium Pharmaceuticals Inc. has recently filed a lawsuit against Watson Pharmaceuticals and its subsidiary, claiming that the company infringed on 10 FCB patents for its Testim product. In its 1st quarter, Auxilium saw sales of Testim rise by 27% to $58.7 million. Increased Testim sales helped narrow Auxilium's quarterly loss to $0.04 from $.25 a year ago. Auxilium Pharmaceuticals Inc. research report is available for free by signing up now at www.stockcall.com/AUXL30512.pdf.

On the generic launch front, Perrigo Co. has been particularly active. The company recently received approval from the FDA for its generic equivalent of Gynazole·1®, and has also been granted approval to market a generic equivalent of Novartis' Prevacid. Both new generics should positively impact Perrigo's financials moving forward. Perrigo Co. research report is accessible for free by registering today at www.stockcall.com/PRGO300512.pdf.

Visit www.stockcall.com/ to see how companies in this industry have grown over the past years and how they are expected to perform in the future.

About StockCall.com
StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information